Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Oct 7;138(14):1278-1281.
doi: 10.1182/blood.2021012769.

Response to SARS-CoV-2 vaccination in patients after hematopoietic cell transplantation and CAR T-cell therapy

Binod Dhakal  1 , Sameem Abedin  1 , Timothy Fenske  1 , Saurabh Chhabra  1 , Nathan Ledeboer  2 , Parameswaran Hari  1 , Mehdi Hamadani  1
Affiliations

Response to SARS-CoV-2 vaccination in patients after hematopoietic cell transplantation and CAR T-cell therapy

Binod Dhakal et al. Blood. .
No abstract available

PubMed Disclaimer

Comment in

  • One step at a time.
    Schoemans H, Ljungman P. Schoemans H, et al. Blood. 2021 Oct 7;138(14):1208-1209. doi: 10.1182/blood.2021013434. Blood. 2021. PMID: 34618004 Free PMC article. No abstract available.

References

    1. Zhu N, Zhang D, Wang W, et al. ; China Novel Coronavirus Investigating and Research Team . A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382(8):727-733. - PMC - PubMed
    1. Baden LR, El Sahly HM, Essink B, et al. ; COVE Study Group . Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2021;384(5):403-416. - PMC - PubMed
    1. Logunov DY, Dolzhikova IV, Shcheblyakov DV, et al. ; Gam-COVID-Vac Vaccine Trial Group . Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. Lancet. 2021; 397(10275):671-681. - PMC - PubMed
    1. Polack FP, Thomas SJ, Kitchin N, et al. ; C4591001 Clinical Trial Group . Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020;383(27):2603-2615. - PMC - PubMed
    1. Sadoff J, Le Gars M, Shukarev G, et al. . Interim results of a phase 1-2a trial of Ad26.COV2.S Covid-19 vaccine. N Engl J Med. 2021;384(19):1824-1835. - PMC - PubMed

Substances